{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:01:19Z","timestamp":1787029279084,"version":"build-2736575974"},"reference-count":73,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>To this day, the use of oily eye drops and non-invasive retinal delivery remain a major challenge. Oily eye drops usually cause ocular irritation and interfere with the normal functioning of the eye, while ocular injections for retinal drug delivery cause significant adverse effects and a high burden on the healthcare system. Here, the authors report a novel topical non-invasive ocular delivery platform (NIODP) through the periorbital skin for high-efficiency anterior and posterior ocular delivery in a non-human primate model (NHP). A single dose of about 7 mg JV-MD2 (omega 3 DHA) was delivered via the NIODP and reached the retina at a Cmax of 111 \u00b5g\/g and the cornea at a Cmax of 66 \u00b5g\/g. The NIODP also delivered JV-DE1, an anti-inflammatory agent in development for dry eye diseases, as efficiently as eye drops did to the anterior segments of the NHP. The topical NIODP seems to transport drug candidates through the corneal pathway to the anterior and via the conjunctiva\/sclera pathway to the posterior segments of the eye. The novel NIODP method has the potential to reshape the landscape of ocular drug delivery. This is especially the case for oily eye drops and retinal delivery, where the success of the treatment lies in the ocular tolerability and bioavailability of drugs in the target tissue.<\/jats:p>","DOI":"10.3390\/pharmaceutics15092344","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T02:26:17Z","timestamp":1695090377000},"page":"2344","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Discovery and Potential Utility of a Novel Non-Invasive Ocular Delivery Platform"],"prefix":"10.3390","volume":"15","author":[{"given":"Weizhen (Jenny)","family":"Wang","sequence":"first","affiliation":[{"name":"Department of R&D, JeniVision Inc., Irvine, CA 92617, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nonna","family":"Snider","sequence":"additional","affiliation":[{"name":"Department of R&D, JeniVision Inc., Irvine, CA 92617, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/archopht.1985.01050010107030","article-title":"Penetration of topical cyclosporine into the rabbit cornea, aqueous humor, and serum","volume":"103","author":"Mosteller","year":"1985","journal-title":"Arch. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1167\/iovs.07-0229","article-title":"Benefits and side effects of different vegetable oil vectors on apoptosis, oxidative stress, and P2X7 cell death receptor activation","volume":"48","author":"Said","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Agarwal, P., Craig, J.P., and Rupenthal, I.D. (2021). Formulation Considerations for the Management of Dry Eye Disease. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13020207"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","article-title":"A comprehensive insight on ocular pharmacokinetics","volume":"6","author":"Agrahari","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1203\/01.PDR.0000072795.38990.F2","article-title":"The influence of prematurity and long chain polyunsaturate supplementation in 4-week adjusted age baboon neonate brain and related tissues","volume":"54","author":"Wijendran","year":"2003","journal-title":"Pediatr. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1194\/jlr.M300106-JLR200","article-title":"Formula feeding potentiates docosahexaenoic and arachidonic acid biosynthesis in term and preterm baboon neonates","volume":"45","author":"Wijendran","year":"2004","journal-title":"J. Lipid Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"120332","DOI":"10.1016\/j.ijpharm.2021.120332","article-title":"Topical drug delivery to the posterior segment of the eye: Thermodynamic considerations","volume":"597","author":"Sripetch","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.addr.2005.09.004","article-title":"Topical and systemic drug delivery to the posterior segments","volume":"57","author":"Hughes","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Tsai, C.H., Wang, P.Y., Lin, I.C., Huang, H., Liu, G.S., and Tseng, C.L. (2018). Ocular Drug Delivery: Role of Degradable Polymeric Nanocarriers for Ophthalmic Application. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092830"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4155\/tde-2017-0088","article-title":"Recent advances in topical nano drug-delivery systems for the anterior ocular segment","volume":"9","author":"Lakhani","year":"2018","journal-title":"Ther. Deliv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1089\/jop.2012.0241","article-title":"Anterior eye segment drug delivery systems: Current treatments and future challenges","volume":"29","author":"Molokhia","year":"2013","journal-title":"J. Ocul. Pharm. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Varela-Fernandez, R., Diaz-Tome, V., Luaces-Rodriguez, A., Conde-Penedo, A., Garcia-Otero, X., Luzardo-Alvarez, A., Fernandez-Ferreiro, A., and Otero-Espinar, F.J. (2020). Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12030269"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11095-018-2519-x","article-title":"Topical Drug Delivery to the Posterior Segment of the Eye: Addressing the Challenge of Preclinical to Clinical Translation","volume":"35","author":"Rodrigues","year":"2018","journal-title":"Pharm. Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kim, H.M., and Woo, S.J. (2021). Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13010108"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1124\/jpet.119.256933","article-title":"Ocular Drug Delivery: Present Innovations and Future Challenges","volume":"370","author":"Gote","year":"2019","journal-title":"J. Pharm. Exp. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1167\/iovs.08-3148","article-title":"Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits","volume":"50","author":"Nomoto","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/smll.201303433","article-title":"Topical delivery of Avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes","volume":"10","author":"Davis","year":"2014","journal-title":"Small"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1167\/iovs.16-20072","article-title":"Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides","volume":"58","author":"Hill","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1600-0420.2007.00885.x","article-title":"Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye","volume":"85","author":"Sigurdsson","year":"2007","journal-title":"Acta Ophthalmol. Scand."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/jop.2017.0121","article-title":"Intravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery","volume":"34","author":"Hartman","year":"2018","journal-title":"J. Ocul. Pharm. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"Rimpela","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_22","first-page":"169","article-title":"Intravitreal Dexamethasone Implant in the Treatment of Non-Infectious Uveitic Macular Edema","volume":"7","author":"Karti","year":"2018","journal-title":"Med. Hypothesis Discov. Innov. Ophthalmol."},{"key":"ref_23","first-page":"789","article-title":"Intravitreal triamcinolone acetonide: A \u201creal world\u201d analysis of visual acuity, pressure and outcomes","volume":"9","author":"Villegas","year":"2016","journal-title":"Int. J. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Cao, L., Weetall, M., Bombard, J., Qi, H., Arasu, T., Lennox, W., Hedrick, J., Sheedy, J., Risher, N., and Brooks, P.C. (2016). Discovery of Novel Small Molecule Inhibitors of VEGF Expression in Tumor Cells Using a Cell-Based High Throughput Screening Platform. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0168366"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.01.021","article-title":"The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders","volume":"129","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"ref_26","unstructured":"Kaiser, P.K. (2022, January 20). Retina Pipeline 2021 Ongoing Innovation Wet AMD. Available online: https:\/\/retinatoday.com\/images\/retina-pipeline\/retina-pipeline-2021\/pdfs-for-download\/Wet-AMD-Retina-Pipeline-Poster.pdf."},{"key":"ref_27","unstructured":"Kaiser, P.K. (2022, January 20). Retina Pipeline 2021 Ongoing Innovation Dry AMD. Available online: https:\/\/retinatoday.com\/images\/retina-pipeline\/retina-pipeline-2021\/pdfs-for-download\/Dry-AMD-Retina-Pipeline-Poster.pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/jop.2018.0126","article-title":"A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method","volume":"35","author":"Woodward","year":"2019","journal-title":"J. Ocul. Pharm. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/iovs.63.1.9","article-title":"Columnar and Laminar Segregation of Retinal Input to the Primate Superior Colliculus Revealed by Anterograde Tracer Injection Into Each Eye","volume":"63","author":"Dilbeck","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1089\/jop.2021.0059","article-title":"N-of-1 Clinical Trials: A Scientific Approach to Personalized Medicine for Patients with Rare Retinal Diseases Such as Retinitis Pigmentosa","volume":"37","author":"Zarbin","year":"2021","journal-title":"J. Ocul. Pharm. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1089\/jop.2016.0069","article-title":"Prostanoid Receptor Antagonist Effects on Intraocular Pressure, Supported by Ocular Biodisposition Experiments","volume":"32","author":"Woodward","year":"2016","journal-title":"J. Ocul. Pharm. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1871527315666151110124957","article-title":"Rabbit Models of Ocular Diseases: New Relevance for Classical Approaches","volume":"15","author":"Zernii","year":"2016","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.bjp.0706554","article-title":"RO1138452 and RO3244794: Characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists","volume":"147","author":"Bley","year":"2006","journal-title":"Br. J. Pharm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/02713688809031801","article-title":"Comparison of conjunctival and corneal surface areas in rabbit and human","volume":"7","author":"Watsky","year":"1988","journal-title":"Curr. Eye Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.addr.2018.03.001","article-title":"The suprachoroidal space as a route of administration to the posterior segment of the eye","volume":"126","author":"Chiang","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Tyagi, P., Kadam, R.S., and Kompella, U.B. (2012). Comparison of suprachoroidal drug delivery with subconjunctival and intravitreal routes using noninvasive fluorophotometry. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0048188"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"25158414211003381","DOI":"10.1177\/25158414211003381","article-title":"The utility and risks of therapeutic nanotechnology in the retina","volume":"13","author":"Scheive","year":"2021","journal-title":"Ther. Adv. Ophthalmol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/eye.1990.41","article-title":"Permeability of ocular vessels and transport across the blood-retinal-barrier","volume":"4","author":"Tornquist","year":"1990","journal-title":"Eye"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Hammadi, S., Tzoumas, N., Ferrara, M., Meschede, I.P., Lo, K., Harris, C., Lako, M., and Steel, D.H. (2023). Bruch\u2019s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration. J. Clin. Med., 12.","DOI":"10.3390\/jcm12082870"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.3389\/fimmu.2017.01778","article-title":"Bruch\u2019s Membrane Compartmentalizes Complement Regulation in the Eye with Implications for Therapeutic Design in Age-Related Macular Degeneration","volume":"8","author":"Clark","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nri3459","article-title":"Immunology of age-related macular degeneration","volume":"13","author":"Ambati","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"13094","DOI":"10.1073\/pnas.2000339117","article-title":"Altered photoreceptor metabolism in mouse causes late stage age-related macular degeneration-like pathologies","volume":"117","author":"Cheng","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"973856","DOI":"10.3389\/fmed.2022.973856","article-title":"The role of the mTOR pathway in diabetic retinopathy","volume":"9","author":"Casciano","year":"2022","journal-title":"Front. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12979-017-0112-5","article-title":"Ageing: From inflammation to cancer","volume":"15","author":"Leonardi","year":"2018","journal-title":"Immun. Ageing"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Zou, Z., Tao, T., Li, H., and Zhu, X. (2020). mTOR signaling pathway and mTOR inhibitors in cancer: Progress and challenges. Cell Biosci., 10.","DOI":"10.1186\/s13578-020-00396-1"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"838263","DOI":"10.3389\/fphar.2022.838263","article-title":"Dihydroartemisinin Inhibits Laser-Induced Choroidal Neovascularization in a Mouse Model of Neovascular AMD","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharm."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Gutierrez, S., Svahn, S.L., and Johansson, M.E. (2019). Effects of Omega-3 Fatty Acids on Immune Cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20205028"},{"key":"ref_48","unstructured":"Department of Ophthalmology, H.M.S (2023, July 27). AMD Treatment Guidelines. Available online: https:\/\/eye.hms.harvard.edu\/eyeinsights\/2015-january\/age-related-macular-degeneration-amd#:~:text=Ninety%20percent%20of%20all%20people,legal%20blindness%20from%20the%20disease."},{"key":"ref_49","unstructured":"Nielsen, M.K. (2023, July 27). Geographic Atrophy. Available online: https:\/\/eyewiki.aao.org\/Geographic_Atrophy#:~:text=It%20starts%20typically%20in%20the,of%20all%20individuals%20with%20AMD."},{"key":"ref_50","first-page":"205","article-title":"The New Era of Omega-3 Fatty Acids Supplementation: Therapeutic Effects on Dry Age-Related Macular Degeneration","volume":"10","author":"Georgiou","year":"2015","journal-title":"J. Stem Cells"},{"key":"ref_51","first-page":"377-F0208","article-title":"A prospective, multicentre, randomised, double-blind study designed to assess the potential effects of omega-3 fatty acids supplementation in dry age-related macular degeneration or Stargardt disease","volume":"63","author":"Prokopiou","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.ophtha.2013.01.005","article-title":"Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration: The Nutritional AMD Treatment 2 study","volume":"120","author":"Souied","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000441359","article-title":"Omega-3 Fatty Acids and Age-Related Macular Degeneration","volume":"55","author":"Souied","year":"2015","journal-title":"Ophthalmic Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1167\/iovs.10-5392","article-title":"Ophthalmic drug delivery systems for the treatment of retinal diseases: Basic research to clinical applications","volume":"51","author":"Edelhauser","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Khoo, H.E., Ng, H.S., Yap, W.S., Goh, H.J.H., and Yim, H.S. (2019). Nutrients for Prevention of Macular Degeneration and Eye-Related Diseases. Antioxidants, 8.","DOI":"10.3390\/antiox8040085"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"748361","DOI":"10.1155\/2011\/748361","article-title":"Retina and omega-3","volume":"2011","author":"Querques","year":"2011","journal-title":"J. Nutr. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3390\/nu2030355","article-title":"Omega-3 fatty acids and inflammatory processes","volume":"2","author":"Calder","year":"2010","journal-title":"Nutrients"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1194\/jlr.M039040","article-title":"Retinoid X receptor activation is essential for docosahexaenoic acid protection of retina photoreceptors","volume":"54","author":"German","year":"2013","journal-title":"J. Lipid Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1074\/mcp.M400003-MCP200","article-title":"Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor alpha ligand-binding domain","volume":"3","author":"Lengqvist","year":"2004","journal-title":"Mol. Cell Proteom."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00210-007-0251-x","article-title":"Peroxisome proliferator activated receptor gamma and oxidized docosahexaenoic acids as new class of ligand","volume":"377","author":"Itoh","year":"2008","journal-title":"Naunyn Schmiedebergs Arch. Pharm."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2125.2012.04374.x","article-title":"Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology?","volume":"75","author":"Calder","year":"2013","journal-title":"Br. J. Clin. Pharm."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1096\/fj.13-235333","article-title":"Cyclooxygenase-2 induction in macrophages is modulated by docosahexaenoic acid via interactions with free fatty acid receptor 4 (FFA4)","volume":"27","author":"Li","year":"2013","journal-title":"FASEB J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41598-018-19252-x","article-title":"Omega-3-carboxylic acids provide efficacious anti-inflammatory activity in models of crystal-mediated inflammation","volume":"8","author":"Iverson","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"10888","DOI":"10.1074\/jbc.M008150200","article-title":"Protein kinase inhibition by omega-3 fatty acids","volume":"276","author":"Mirnikjoo","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s13318-016-0319-4","article-title":"Ocular Drug Distribution After Topical Administration: Population Pharmacokinetic Model in Rabbits","volume":"42","author":"Djebli","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-0625.2000.009003165.x","article-title":"The 500 Dalton rule for the skin penetration of chemical compounds and drugs","volume":"9","author":"Bos","year":"2000","journal-title":"Exp. Dermatol."},{"key":"ref_67","first-page":"165","article-title":"Electron microscopic demonstration of the penetration of liposomes through skin","volume":"43","author":"Schramlova","year":"1997","journal-title":"Folia Biol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Souto, E.B., Macedo, A.S., Dias-Ferreira, J., Cano, A., Zielinska, A., and Matos, C.M. (2021). Elastic and Ultradeformable Liposomes for Transdermal Delivery of Active Pharmaceutical Ingredients (APIs). Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22189743"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Bisht, R., Mandal, A., Jaiswal, J.K., and Rupenthal, I.D. (2018). Nanocarrier mediated retinal drug delivery: Overcoming ocular barriers to treat posterior eye diseases. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 10.","DOI":"10.1002\/wnan.1473"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.2147\/DDDT.S264648","article-title":"Potential of Nanoparticles as Permeation Enhancers and Targeted Delivery Options for Skin: Advantages and Disadvantages","volume":"14","author":"Ghasemiyeh","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ijpharm.2015.05.042","article-title":"LeciPlex, invasomes, and liposomes: A skin penetration study","volume":"490","author":"Shah","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_72","unstructured":"(2023, July 27). NanoSense Lesson 2: Scale of Objects, Student Materials. Available online: https:\/\/nanosense.sri.com\/activities\/sizematters\/sizeandscale\/SM_Lesson2Student.pdf."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"418316","DOI":"10.1155\/2011\/418316","article-title":"Characterization and In Vitro Skin Permeation of Meloxicam-Loaded Liposomes versus Transfersomes","volume":"2011","author":"Duangjit","year":"2011","journal-title":"J. Drug Deliv."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/9\/2344\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:53:29Z","timestamp":1760129609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/9\/2344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":73,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["pharmaceutics15092344"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15092344","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]}}}